Knee Injections for the Clinical Management of Knee OsteoArthritis (KICK-OA)

Knee osteoarthritis (OA) is an incurable disease that involves breakdown of the knee joint. This breakdown is often accompanied by knee pain and stiffness, which can limit a person's daily physical activity. Fortunately, there are treatments that may stop or slow the progression of knee OA. Bone marrow aspirate can be extracted and processed into autologous, nucleated cells, then injected back into the knee affected by OA. These cells provide important nutrients that can improve the health of the knee joint and alleviate the symptoms of knee OA.

Therefore, the investigators are interested in determining whether an injection of autologous, nucleated cells can improve physical activity, pain and function in people who are diagnosed with knee OA.

The investigators will recruit a total of 100 subjects for this study and examine changes in physical activity using a research-grade Actigraph Monitor.

Study Overview

• Status: Withdrawn
• Conditions: Knee Osteoarthritis
• Intervention / Treatment: Device: Arthrex Angel System used to prepare injection of Bone Marrow Concentrate (BMC); Other: Saline injection

• Study Type: Interventional
• Phase: Not Applicable

Contacts and Locations

Study Locations

• United States
  • Delaware
    • Newark, Delaware, United States, 19713
      • University of Delaware

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 40 years to 79 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Adults 40-79 years of age
• Doctor-diagnosed knee OA

Exclusion Criteria:

Related to knee OA diagnosis:

• Seeking treatment for end-stage knee OA (Kellgren-Lawrence Grade 4 on X-ray)
• Seeking advanced treatment options for knee OA (e.g., knee replacement) within 6 months
• Seeking treatment for bilateral symptomatic knee OA

Related to current health status or medical history:

• Findings on clinical examination that preclude safe participation in the study, including (but not limited to):

  • 3+ effusion of the target knee
  • Significant varus or valgus alignment deformity
• Non-ambulatory (e.g., use a manual or power wheelchair)
• Diagnosis of rheumatoid arthritis, inflammatory arthritis, or gout
• Uncontrolled diabetes (e.g., glycosylated hemoglobin level >7.0)
• Known contraindications to MRI, including: heart pacemaker, artificial heart valves, metal implants such as metal ear implants, bullet pieces, chemotherapy or insulin pumps, metal clips or rings
• Body mass index > 40 kg/m 2
• Increased risk for postsurgical bleeding (e.g., bleeding disorder or taking anticoagulants except low-dose aspirin)
• Increased risk for postsurgical infection (e.g., taking immunosuppressants, having a severe infection, or a having a history of serious infection)
• Known allergy to lidocaine or other anesthetics
• History of anemia
• Recent infection of target knee (within last month) requiring antibiotics
• History of bone marrow harvest or biopsy at any time
• Active malignancy or history of bone marrow malignancy

Related to previous OA management:

• Previous corticosteroid injection in the target knee within the last 3 months
• Previous viscosupplementation injection in the target knee within the last 6 months
• Previous PRP or stem cell injection in the target knee
• Previous surgery in the target knee within the last 12 months
• Previous partial or total knee replacement of the target knee
• Recent or planned surgery in the lower extremity of the target knee within 6 months

Related to other personal factors:

• Impaired cognition that impacts the ability to give informed consent
• Intense fear of needles
• Intense fear of small, enclosed spaces (i.e., claustrophobia)
• Unable to remain still for duration of MRI procedure without a sedative or anesthetic
• Likely unable to attend follow-up study visits over 6 months while enrolled in the study

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Triple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Intervention Group; Injection of Bone Marrow Concentrate (BMC)	Device: Arthrex Angel System used to prepare injection of Bone Marrow Concentrate (BMC); Participants will have bone marrow aspirated from their iliac crest, then processed using the Arthrex Angel System to produce autologous bone marrow concentrate (BMC). Then, BMC will be injected into the participant's knee with knee osteoarthritis (OA).
Placebo Comparator: Control Group; Injection of saline	Other: Saline injection; Participants will have bone marrow aspirated from their iliac crest to maintain masking. Then, saline will be injected into the participant's knee with knee osteoarthritis (OA).

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Physical Activity	The investigators will use the Actigraph GT3X (Actigraph LLC, Pensacola, FL) to objectively measure physical activity. The Actigraph GT3X is a hip-worn accelerometer that measures the intensity of physical activity on a minute-by-minute basis. The Actigraph GT3X is valid and reliable in community-dwelling older adults with knee OA.	Change in physical activity from baseline to 3 months.

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Pain of Target Knee	The investigators will ask participants to complete the Visual Analog Scale (VAS), a single-item instrument in which the participant makes a mark on a 100 mm line to indicate their pain score in each knee from 0-100. A higher score indicates greater pain intensity of the target knee. The instrument takes <1 minute to complete.	Change in pain of target knee from baseline to 3 weeks, and change in pain of target knee from baseline to 3 months.
Function of Target Knee	The investigators will ask participants to complete the Knee Injury and Osteoarthritis Outcome Score (KOOS), a 42-item instrument that assesses the following five domains: pain, symptoms (other than pain), function in activities of daily living, function in sport and recreation, and quality of life. The score is a percentage score from 0 to 100, 0 representing extreme problems of the target knee and 100 representing no problems of the target knee. The instrument takes approximately 10 minutes to complete.	Change in function of target knee from baseline to 3 weeks, and change in function of target knee from baseline to 3 months.

Collaborators and Investigators

• Sponsor: University of Delaware
• Investigators: Principal Investigator: Daniel K White, PT, ScD, MSc, University of Delaware

Study record dates

Study Major Dates

• Study Start (Estimated): September 1, 2022
• Primary Completion (Estimated): September 1, 2023
• Study Completion (Estimated): September 1, 2024

Study Registration Dates

• First Submitted: October 8, 2020
• First Submitted That Met QC Criteria: October 20, 2020
• First Posted (Actual): October 22, 2020

Study Record Updates

• Last Update Posted (Actual): October 2, 2023
• Last Update Submitted That Met QC Criteria: September 28, 2023
• Last Verified: September 1, 2023

More Information

Terms related to this study

• Keywords: MRI; Physical Activity; Autologous Nucleated Cells
• Additional Relevant MeSH Terms: Joint Diseases; Musculoskeletal Diseases; Rheumatic Diseases; Arthritis; Osteoarthritis; Osteoarthritis, Knee
• Other Study ID Numbers: 1893057

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: Yes